(Sharecast News) - Bayer reported a major boost to its drug pipeline on Monday morning, after its experimental anticoagulant asundexian delivered positive results in a large phase three trial, easing concerns following a setback last year and lifting investor sentiment.
The company said the once-daily, 50-milligram treatment significantly reduced the risk...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE